An interventional study of BL-Predicter in Drug Allergy, sponsored by Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud. Not yet recruiting. Open to participants aged 14 Years and older. Per ClinicalTrials.gov, last updated 2025-06-08.
Sponsored by Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud · Not applicable, Interventional, and Treatment
Testing a clinical decision tool (BL-Predictor)
1,914 studies on the registry are indexed under Hypersensitivity; 265 are open to participants now.
This study's planned enrollment of 332 is above the median of 57 across 1,382 interventional studies indexed under Hypersensitivity.
Browse Hypersensitivity studies →Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud is the lead sponsor of 71 studies on the registry; 23 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Parallel,non-inferiority, randomised control trial will be conducted in patients with a low-risk score stratified by BL-Predictor
Diagnostic Test: BL-Predicter
St followed, if negative,by a fractioned dose DTP wirth 30 min interval between doses: 25%-25%-50% of the maximun dose
Diagnostic Test: BL-Predicter
To Clinically validate the BL-Predictor toll by a randomised conytrolled ttrial
The main goal of this project is to test a cliniacl decision toll to stratify BL allergic pataients in low and mediaum- anf high-risk
And to carry out a deep dissection of the cellular mechanisms of B cells sensitization and basophil and neutrophil activation in BL-IRs to develop accurate in vitro diagnostic test
Time frame: April 2029- june 2027
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud